English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Thursday, June 9, 2022
中国抗体公布SN1011新药研究申请获中国国家药品监督管理局药品审评中心受理
中國抗體公佈SN1011新藥研究申請獲中國國家藥品監督管理局藥品審評中心受理
SinoMab Announces IND Application for SN1011 Accepted by NMPA CDE
Wednesday, April 20, 2022
中国抗体公布SN1011新药研究申请获国家药监局批准
中國抗體公佈SN1011新藥研究申請獲國家藥監局批准
SinoMab Announces IND APPLICATION FOR SN1011 APPROVED BY NMPA
Monday, March 14, 2022
中国抗体用于哮喘的第一类治疗产品SM17新药研究申请获FDA批准
中國抗體用於哮喘的第一類治療產品SM17新藥研究申請獲FDA批准
IND Application for SinoMab's First-in-Class Asthma Therapeutic Product SM17 Approved by FDA
Thursday, February 17, 2022
IND Application for SinoMab's First-in-Class Asthma Therapeutic Product SM17 Accepted by FDA

Copyright © 2023 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575